Hikma

Hikma Pharmaceuticals PLC

Hikma delivers strong H1 performance and upgrades Group guidance

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharm...

  • 6 months ago

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it ...

  • 12 months ago

Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an excl...

  • 1 year ago

Hikma continues strong momentum across the Group and upgrades guidance for 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutica...

  • 1 year ago

Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical compa...

  • 1 year ago

Hikma and Rakuten Medical sign exclusive licensing agreement for AlluminoxTM platform cancer treatment for the Middle East and North Africa

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical comp...

  • 1 year ago

Hikma delivers strong H1 performance and raises Generics guidance Growth in all three businesses and across all geographies

Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational ...

  • 2 years ago

Good momentum across all businesses and updated Generics guidance

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutica...

  • 2 years ago

Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC

Amman,Jordan — Hikma Pharmaceuticals PLC (Hikma, Group), announces that Riad Mishlawi, President o...

  • 2 years ago

Hikma delivers a resilient underlying performance in 2022

Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmace...

  • 2 years ago

Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical comp...

  • 2 years ago

Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for the Middle East and North Africa region

London, England — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, an...

  • 2 years ago

Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, annou...

  • 2 years ago

Hikma’s diversified business delivers resilient H1 performance

London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational...

  • 3 years ago

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical compa...

  • 3 years ago

Siggi Olafsson to step down as Chief Executive

London, United Kingdom - Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has r...

  • 3 years ago

Find us here

Lan »